

10/5/9102  
DT01 Rec'd PCT/PTC 27 DEC 2004

DESCRIPTION

DRUG COMPOSITION FOR BLOOD SUGAR CONTROL

5 **Technical Field**

The present invention relates to a pharmaceutical composition for glycemic control of a type II diabetic patient which contains mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof and which is prepared as a pharmaceutical composition to be taken before meals, and a method of uses thereof. The present invention also relates to a method for glycemic control of a type II diabetic patient, which comprises of administrating mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof before meals, and to a use of mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof for the manufacture of a pharmaceutical composition for glycemic control of a type II diabetic patient.

20 **Background Art**

Diabetes is classified briefly into type I diabetes, type II diabetes, diabetes due to other certain mechanism or disorders, and gestational diabetes mellitus. Type I diabetes used to be called juvenile-onset diabetes or insulin dependent diabetes mellitus (IDDM), and type II diabetes used to be called adult-onset type diabetes mellitus or noninsulin dependent diabetes mellitus (NIDDM).

Diabetes is diagnosed in a patient when any of the following results is confirmed at both of twice examinations held on different days: 1) casual plasma glucose is not less than 200 mg/dL, 2) early morning fasting plasma glucose (FPG) is not less than 126 mg/dL, or 3) 2 hour value of 75 g oral glucose tolerance test is not less than 200 mg/dL. In a case that HbA<sub>1c</sub> value is not less than 6.5%, diabetes is determined in a patient when the result meets any above-mentioned criterion even in one-time examination (see Reference 1).

Glycemic control is set up as a target for treatment of these diabetic patients, and the purposes are to maintain their quality of dairy life (QOL) like healthy people and to ensure their lives like healthy people by maintaining their good state of glycemic control, and furthermore, to prevent development and progression of diabetic microvascular complications (diabetic retinopathy, diabetic nephropathy, diabetic neuropathy and the like) and arteriosclerotic diseases (ischemic heart disease, cerebrovascular disease, arteriosclerosis obliterans and the like). HbA<sub>1c</sub> value is used as a primary indication, and the targeted value is preferably not more than 7% and more preferably less than 6.5%. In addition, a 2 hour value of postprandial plasma glucose and a fasting plasma glucose are used as supportive indications of HbA<sub>1c</sub> value. Two hundred (200) mg/dL for 2 hour value of postprandial plasma glucose and 100 to 140 mg/dL for fasting plasma glucose are targeted, respectively (see References 2 and 3).


In a recent large-scale clinical study in the UK on type

II diabetes, the importance of glycemic control for treatment of diabetes has been confirmed. For example, 0.9% decrease in HbA<sub>1c</sub> value caused 10% reduction of diabetes-associated mortality. And, it has been reported that the occurrence of 5 cardiac infarction and microvascular complication notably decreased by 16% and 25%, respectively, and that provides good effects on development and progression of diabetic complications (see Reference 4). Furthermore, it has been reported that overt diabetic nephropathy is increasingly frequent with HbA<sub>1c</sub> value 10 over 7.5% and diabetic retinopathy occurs in high frequency in cases with fasting plasma glucose of 140 mg/dL or more.

As mentioned above, glycemic control is important for treatment of diabetic patients, and in order to maintain a good state of glycemic control, it is necessary to administrate 15 appropriate doses in adequate usages under careful administration plans depending on the types, activities, dispositions and the like of used drugs. In addition, the points to pay attention in glycemic control are not causing any prolonged hypoglycemia and steadily controlling intraday blood glucose 20 level including postprandial and fasting blood glucose.

Mitiglinide calcium salt hydrate (the chemical name: (+)-monocalcium bis[(2S, 3a, 7a-cis)- $\alpha$ -benzylhexahydro- $\gamma$ -oxo-2-isoindolinebutyrate] dihydrate) is a rapid- and short-acting insulin secretagogue having the following chemical 25 structure, and known as a compound expected as an agent to correct a postprandial hyperglycemic state. However, anything has not been reported on the disposition, the methods of use for glycemic

control or the like of mitiglinide.



In addition, there is a report on a immediate release formulation which comprises mitiglinide calcium salt hydrate  
5 as an active ingredient. However, it is just an immediate release formulation, which is not prescribed only based on the disposition of mitiglinide but also the use for glycemic control.

Reference 1: [The guide for treatment of diabetes 2002-2003], edited by The Japan Diabetes Society, Edition 1,  
10 Bunkodo Inc., May 9, 2002, p.14-15;

Reference 2: [The guide for treatment of diabetes 2002-2003], edited by The Japan Diabetes Society, Edition 1,  
Bynkodo Inc., May 9, 2002, p.18-19;

Reference 3: [Today's treatment drugs, Explanations and  
15 Handbook (Konnichi-no-chiryoyaku Kaisetsu-to-binran)], edited by Yu Mizushima, Edition 24, Nankodo Inc., March 15, 2002, p.297;

Reference 4: [Lancet], September 12, 1998, Vol.352,  
No.9131, p.837-853;

Reference 5: Japan Patent Publication No.356459/1992

20 Reference 6: International Patent Publication  
No.2000/71117 pamphlet.

**Disclosure of the Invention**

The present inventors have studied earnestly on the activities and disposition of mitiglinide or pharmaceutically acceptable salts thereof, or hydrates thereof, and established 5 an appropriate dosage and usage. Using a pharmaceutical composition prepared based on the findings obtained those studies, the inventors conducted a clinical study as described below. As a result, it was found that by administrating mitiglinide calcium salt hydrate in a manner as described below, an excellent 10 glycemic control is achieved and postprandial hyperglycemia is efficiently inhibited, furthermore, early morning fasting hyperglycemia is inhibited, and the frequencies of concerned hypoglycemic symptoms and gastrointestinal disorders are low, and that said dosage and usage are extremely effective to prevent 15 and treat type II diabetes, and thereby the present invention has been completed.

The present invention is to provide an excellent pharmaceutical composition for glycemic control of a type II diabetic patient and a method of use the same. Moreover, the 20 present invention is to provide a preferable method of use of the pharmaceutical composition for type II diabetic patients.

For more details, the present inventors found that the required dosage of mitiglinide or a pharmaceutically acceptable salt thereof, or hydrate thereof to reduce HbA<sub>1c</sub> value 25 significantly is 5 mg and more as a single dose and that the half-life in disposition is of the said dose about 1.5 hour. Based on the findings, the inventors evaluated an appropriate

dosage and usage, and as a result, it was found that by administrating 5 to 45 mg, or preferably 5 to 22 mg of mitiglinide calcium salt hydrate three times a day before each meal (within 10 minutes before starting meal), preferably just before meal 5 (within 5 minutes before starting meal), for 4 weeks or more, the HbA<sub>1c</sub> value significantly decrease and the glycemic control can be improved, and in addition, the frequencies of hypoglycemic symptoms and gastrointestinal disorders such as an increase of abdominal wind are low. Moreover, it was found that an increase 10 of postprandial blood glucose level are markedly suppressed, an excellent hypoglycemic action is exerted even after 2 hours after meal, and in addition, early morning fasting plasma glucose is significantly suppressed. The present invention is based on these findings.

15 That is, the present invention relates to a pharmaceutical composition for glycemic control of a type II diabetic patient, which is prepared for administration before meal and comprises 5 to 45 mg of mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof as a single dose, and relates to 20 a use of the pharmaceutical composition for glycemic control of a type II diabetic patient and for prevention or treatment of type II diabetes.

The present invention also relates to a method for glycemic control and a method for improvement of postprandial 25 hyperglycemia in a type II diabetic patient, which comprises administrating before meal 5 to 45 mg of mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof

as a single dose.

Moreover, the present invention relates to a use of mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof for the manufacture of the above pharmaceutical composition for administration before meal to control blood glucose in a type II diabetic patient.

Further details are described about the present invention below.

In the present invention, the term of "postprandial hyperglycemia" means that a 1 hour value and/or a 2 hour value of postprandial plasma glucose (PPG) are not less than 200 mg/dL including that a casual plasma glucose level or 2 hour level of a 75 g oral glucose tolerance test is not less than 200 mg/dL. In addition, the term of "fasting hyperglycemia" means that early morning fasting plasma glucose (FPG) is not less than 126 mg/dL.

The target patients in the present invention are type II diabetic patients, especially type II diabetic patients who require to control their blood sugar. As a more applicable case, a patient with postprandial hyperglycemia is illustrated, and a patient with postprandial hyperglycemia accompanied with fasting hyperglycemia can be also illustrated. As a pharmaceutically acceptable salt of mitiglinide, an salt with an inorganic base such as a sodium salt, a potassium salt, a calcium salt and the like, a salt with an organic amine or an amino acid such as morpholine, piperidine, phenylalanine, and the like can be illustrated, and a calcium salt is preferable. In addition, as an active ingredient in the present invention,

mitiglinide calcium salt hydrate is the most preferable. To maintain the good state of glycemic control, orally administrating 5 to 45 mg as a single dose of mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof  
5 is preferable, and by administration in such a manner, not only glycemic control but also 1 hour and 2 hour values of postprandial plasma glucose and early morning fasting plasma glucose level can be improved. As an amount of a single dose, 5 to 22 mg is preferable, using 10 to 11 mg of mitiglinide calcium salt hydrate  
10 is more preferable. An administration method is administration basically before meal (within 10 minutes before starting meal) or preferably just before meal (within 5 minutes before starting meal), three times a day, and treatment period is preferably 4 weeks or more. In addition, the most preferable is  
15 administrating 10 to 11 mg of mitiglinide calcium salt hydrate as a single dose (to be adjusted in consideration of the symptoms) before meal (within 10 minutes before starting meal), preferably just before meal (within 5 minutes before starting meal), tree times a day for 4 weeks or more.

20 Mitiglinide or pharmaceutically acceptable salts thereof, or hydrates thereof as an active ingredient of the present invention can be easily prepared by the methods described in Japan Patent Publication No.356459/1992 pamphlet, Japan Patent Publication No.340622/1994 pamphlet and Japan Patent  
25 Publication No.340623/1994 pamphlet or similar methods thereto.

As pharmaceutical compositions used in the present invention, oral pharmaceutical compositions such as granules,

fine granules, powders, tablets, capsules or the like can be illustrated.

These pharmaceutical compositions can be prepared by admixing with appropriate pharmaceutical additives such as 5 diluents, binders, surfactants, lubricants, glidants, coating materials, plasticizers, coloring agents, flavoring agents and the like in a usually used way pharmaceutically, and formulating in accordance with conventional methods.

Diluents can include, for example, cellulose or cellulose 10 derivatives such as microcrystalline cellulose and the like; starch or starch derivatives such as corn starch, wheat starch, cyclodextrin and the like; sugar or sugar alcohol such as lactose, D-mannitol and the like; and inorganic diluents such as dried aluminum hydroxide gel, precipitated calcium carbonate, 15 magnesium aluminometasilicate, dibasic calcium phosphate and the like.

Binders can include, for example, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, povidone, dextrin, pullulan, hydroxypropyl starch, polyvinyl alcohol, 20 gum arabic, agar, gelatin, tragacanth, macrogol and the like.

Surfactants can include, for example, sucrose esters of fatty acids, polyoxyl stearate, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, sorbitan sesquioleate, sorbitan trioleate, sorbitan monostearate, 25 sorbitan monopalmitate, sorbitan monoleaurate, polysorbate, glycerylmonostearate, sodium lauryl sulfate, lauromacrogol and the like.

Lubricants can include, for example, stearic acid, calcium stearate, magnesium stearate, talc and the like.

Glidants can include, for example, dried aluminum hydroxide gel, magnesium silicate and the like.

5 Coating materials can include, for example, hydroxypropylmethylcellulose 2910, aminoalkyl methacrylate copolymer E, polyvinylacetal diethylaminoacetate, macrogol 6000, titanium oxide and the like.

10 Plasticizers can include, for example, triethyl citrate, triacetin, macrogol 6000 and the like.

Among pharmaceutical compositions of the present invention, an immediate release formulation is preferable, which can be formulated, for example, by the method described in International Patent Publication No.2000/71117 pamphlet or 15 similar methods thereto.

In the pharmaceutical compositions of the present invention, other hypoglycemic drug(s) can be suitably combined (admixed) with mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient. 20 Furthermore, the pharmaceutical compositions of the present invention can be suitably used (in combination) with other hypoglycemic drug(s) at the same time or different times. Examples of the drugs which can be used in combination with the compounds of the present invention include an insulin sensitivity 25 enhancer (pioglitazone hydrochloride, rosiglitazone maleate and the like), a glucose absorption inhibitor (voglibose, acarbose, miglitol and the like), a biguanide (metformin

hydrochloride, buformin hydrochloride and the like), an insulin secretion enhancer (tolbutamide, acetohexamide, tolazamide, glyclopypamide, glybzole, glyburide / glibenclamide, gliclazide, glimepiride and the like), and an insulin preparation  
5 and the like.

[Examples]

The present invention is further illustrated in more detail by way of the following Test Examples and Examples. However,  
10 the present invention is not limited thereto.

Example 1

After 275.0 g of microcrystalline cellulose, 279.0 g of lactose, 100.0 g of corn starch, 30.0 g of low substituted  
15 hydroxypropylcellulose (brand name: L-HPC/LH-11, produced by Shin-Etsu Chemical Co., Ltd.), 8.0 g of calcium stearate and 8.0 g of light anhydrous silicic acid (brand name: Adsolider<sup>TM</sup> 101, produced by Freund Industrial Co., Ltd.) were mixed with 50.0 g of mitiglinide calcium salt hydrate, the mixture was  
20 compressed by a tabletting machine to prepare tablets of the following composition.

	Active component	10.0 mg
	Microcrystalline cellulose	55.0 mg
	Lactose	55.8 mg
25	Corn starch	20.0 mg
	Low substituted hydroxypropylcellulose	6.0 mg
	Calcium stearate	1.6 mg

Light anhydrous silicic acid	1.6 mg
[Total]	150.0 mg

**Example 2**

5        After 275.0 g of microcrystalline cellulose, 274.0 g of lactose, 100.0 g of corn starch, 30.0 g of low substituted hydroxypropylcellulose (brand name: L-HPC/LH-11, produced by Shin-Etsu Chemical Co., Ltd.), 8.0 g of calcium stearate and 8.0 g of light anhydrous silicic acid (brand name: Adsolider™ 101, produced by Freund Industrial Co., Ltd.) were mixed with 55.0 g of mitiglinide calcium salt hydrate, the mixture was compressed by a tabletting machine to prepare tablets of the following composition.

Active component	11.0 mg
Microcrystalline cellulose	55.0 mg
Lactose	54.8 mg
Corn starch	20.0 mg
Low substituted hydroxypropylcellulose	6.0 mg
Calcium stearate	1.6 mg
Light anhydrous silicic acid	1.6 mg
[Total]	150.0 mg

**Test Example 1****Dissolution test**

25        For the following tablets, the dissolution test was carried out using 900 mL of the first fluid of the Japanese Pharmacopoeia as a test solution and at 50 rpm, according to the paddle method,

apparatus 2 of the dissolution test methods of the 13th revised Japanese Pharmacopoeia.

[Table 1]

Tablet	% of dissolution at 20 min after the beginning of the test
Example 1	>75
Example 2	>75

5 The results on the percentages of dissolution at 20 min after the beginning of the test are shown in Table 1. It has been confirmed that the dissolution time for 75% release in the first fluid of the Japanese Pharmacopoeia of these tablets of Examples 1 and 2 are not more than 20 minutes.

10

Example 3

Clinical study in type II diabetic patients

Using the pharmaceutical composition described in Example 1, a clinical study was conducted in type II diabetic patients 15 under the following conditions.

Inclusion criteria: a type II diabetic patient who did not achieve sufficient glycemic control with diet therapy, more particularly, who has been put on diet therapy since more than 8 weeks before the start of the test drug administration, but 20 the both results of the twice HbA<sub>1c</sub> measurement are not less than 6.5%, and the 1 hour or 2 hour value of postprandial plasma glucose (PPG) is not less than 200 mg/dL.

Test drug and Mode of administration: Every patient orally administered either of a combination selected from the

following combination groups (one tablet from each) three times a day just before meals (within 5 minutes before starting meal):

The present invention group: (1) + (4)

Positive control group: (2) + (3)

5 Positive control group: (3) + (4)

(1) a tablet comprising 10 mg of mitiglinide calcium salt hydrate;

(2) a tablet comprising 0.2 mg of voglibose (chemical name:

(+)-1L-[1(OH),2,4,5/3]-5-[2-hydroxy-1-(hydroxymethyl)-

10 ethyl]amino-1-C-(hydroxymethyl)-1,2,3,4-cyclohexaneterol);

(3) a placebo tablet of mitiglinide calcium salt hydrate not containing any active ingredient; and

(4) a placebo tablet of voglibose not containing any active ingredient.

15 Treatment period: 12 weeks

Observation item: The following items were measured before administration, at a certain fixed time after the start of administration and at the completion of administration, and their changes were calculated, or the frequency of adverse drug reactions was calculated, and then evaluated.

[1] Change in HbA<sub>1c</sub> value

[Table 2]

Treatment Group	Mean value(%)			
	4 weeks	8 weeks	12 weeks	The final evaluation
The present invention group	-0.30	-0.46	-0.46	-0.44
Positive control group	-0.14	-0.14	-0.11	-0.11
Placebo group	0.02	0.14	0.22	0.21

The result on the changes in HbA<sub>1c</sub> value is shown in the above Table 2. Mitiglinide calcium salt hydrate significantly lowered HbA<sub>1c</sub> value after 4 weeks after the start of administration  
 5 in comparison with voglibose as the positive control and placebo, and voglibose significantly lowered HbA<sub>1c</sub> value in comparison with placebo. From the results mentioned above, it has been confirmed that mitiglinide calcium salt hydrate shows a potent activity lowering HbA<sub>1c</sub> value and has excellent efficacy to  
 10 improve glycemic control state.

[2] Change in early morning fasting plasma glucose (FPG)

[Table 3]

Treatment Group	Mean (mg/dL)
The present invention group	-8.0
Positive control group	0.5
Placebo group	7.1

The result on the changes in early morning fasting plasma glucose (FPG) is shown in the above Table 3 (the mean values in the table indicate values at the final evaluation). Mitiglinide calcium salt hydrate significantly lowered early

morning fasting plasma glucose (FPG) in comparison with voglibose as the positive control and placebo. Therefore, it has been confirmed that mitiglinide calcium salt hydrate shows a potent activity to lower early morning fasting plasma glucose (FPG).

5 [3] Change in 1 hour and 2 hour values of postprandial plasma glucose (PPG)

[Table 4]

Treatment Group	Mean value(mg/dL)	
	1 hour value of PPG	2 hour value of PPG
The present invention group	-53.1	-50.1
Positive control group	-24.8	-5.1
Placebo group	7.1	9.9

10 The result on the changes in 1 hour and 2 hour values of postprandial plasma glucose (PPG) is shown in the above Table 4 (the mean values in the table indicate values at the final evaluation). Mitiglinide calcium salt hydrate significantly lowered 1 hour and 2 hour values of postprandial plasma glucose (PPG) in comparison with voglibose as the positive control and 15 placebo. Therefore, it has been confirmed that mitiglinide calcium salt hydrate shows a potent activity to lower postprandial plasma glucose (PPG).

[4] Frequency of adverse drug reactions of hypoglycemic symptoms and gastrointestinal disorder

20 [Table 5]

Treatment Group	Frequency(%)	
	Hypoglycemic symptoms	Gastrointestinal disorder
The present invention group	2.0	17.6
Positive control group	4.5	24.5
Placebo group	2.9	16.7

The result on the frequencies of adverse drug reactions of hypoglycemic symptoms and gastrointestinal disorders is shown in the above Table 5. Mitiglinide calcium salt hydrate decreased the frequencies of hypoglycemic symptoms and gastrointestinal disorders such as an increase of abdominal wind in comparison with voglibose as the positive control. Therefore, it has been confirmed that mitiglinide calcium salt hydrate is a highly safe agent with low incidences of those adverse drug reactions.

10

#### Example 4

##### Clinical study on administration timing

Administration timing before taking a meal was evaluated in healthy male adults. Used test drugs were a tablet comprising 15 10 mg of mitiglinide calcium salt hydrate and a placebo tablet. The tablet comprising 10 mg of mitiglinide calcium salt hydrate was administered at 0.5 min, 5 min, 10 min or 30 min before starting meal (Positive group), while the placebo tablet was administered at 0.5 min before starting meal. After administration, blood 20 glucose levels were measured at starting meal and evaluated.

[Table 6]

Treatment Group	Administration timing	Mean (mg/dL)
Positive group	0.5 min before starting meal	87.0
	5 min before starting meal	83.8
	10 min before starting meal	84.2
	30 min before starting meal	55.7
Placebo group	0.5 min before starting meal	85.6

The result is shown in the above Table 6. Mitiglinide calcium salt hydrate was able to maintain good blood glucose level when administrated within 10 minutes before starting meal,  
 5 while the blood glucose level notably declined when it was administered at 30 minutes before starting meal. Therefore, it has been confirmed that the risk of hypoglycemia incidence can be reduced by administrating mitiglinide calcium salt hydrate within 10 minutes before starting meal. In addition,  
 10 administration within 5 minutes before starting meal was preferable from the point of view of the administration compliance.

#### Industrial Applicability

15 The present invention can provide a clinically effective, excellent pharmaceutical composition for prevention or treatment of type II diabetes, which can achieve good state of glycemic control and correct postprandial hyperglycemia and early morning fasting hyperglycemia, further, with low frequency  
 20 of adverse drug reactions such as hypoglycemic symptoms and

**gastrointestinal disorders.**